Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Esperion Therapeutis.Inc. buy StockNews.com

Esperion Therapeutis.Inc.
Start price
€1.93
26.10.24 / 50%
Target price
-
26.10.25
Performance (%)
18.51%
End price
€2.29
27.10.25
Summary
This prediction ended on 27.10.25 with a price of €2.29. The prediction had a final performance of 18.51%. StockNews_com has a follow-up prediction for Esperion Therapeutis.Inc. where he still thinks Esperion Therapeutis.Inc. is a Buy. StockNews_com has 50% into this prediction

Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.

Performance without dividends (%)
Name 1w 1m 1y
Esperion Therapeutis.Inc. -15.826% -15.826% 27.110%
iShares Core DAX® 0.721% 4.566% 24.333%
iShares Nasdaq 100 -0.413% 1.884% 8.848%
iShares Nikkei 225® 3.500% 7.196% 24.030%
iShares S&P 500 0.489% 2.436% 6.048%

Comments by StockNews_com for this prediction

In the thread Esperion Therapeutis.Inc. diskutieren

Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat

StockNews.com 
0
Report Share
26.10.24 Buy 18.51%
In the thread Trading Esperion Therapeutis.Inc.
Prediction Buy
Perf. (%) 18.51%
Target price
Change
Ends at 26.10.25

Die von StockNews_com gewählte maximale Laufzeit wurde überschritten

StockNews.com 
0
Report Share
27.10.25

Current prediction by StockNews_com for Esperion Therapeutis.Inc.

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.70
17.08.25
-
17.08.26
63.62%
14.01.26

StockNews.com 
17.08.25 50%

Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.97
05.10.24
-
05.10.25
41.81%
06.10.25

StockNews.com 
05.10.24 50%